67. 多発性嚢胞腎 Polycystic kidney disease Clinical trials / Disease details

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03203642 (ClinicalTrials.gov)	October 12, 2017	26/6/2017	Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD	A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinibin Subjects ...	Autosomal Dominant Polycystic Kidney;ADPKD	Drug: Tesevatinib;Drug: Placebo	Kadmon, a Sanofi Company	NULL	Completed	18 Years	60 Years	All	80	Phase 2	United States
2	NCT03096080 (ClinicalTrials.gov)	August 24, 2017	6/3/2017	A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinibin Pediatric Subjects With Auto ...	A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinibin Pediatric Subjects ...	Polycystic Kidney, Autosomal Recessive	Drug: Tesevatinib	Kadmon Corporation, LLC	NULL	Completed	5 Years	12 Years	All	10	Phase 1	United States
3	NCT02616055 (ClinicalTrials.gov)	December 25, 2015	24/11/2015	Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinibon S ...	Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinibon S ...	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: tesevatinib	Kadmon Corporation, LLC	NULL	Terminated	18 Years	62 Years	All	15	Phase 2	United States
4	NCT01559363 (ClinicalTrials.gov)	December 7, 2012	9/3/2012	A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polyc ...	A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 ((Tesevatinib) in Subjects ...	Polycystic Kidney, Autosomal Dominant	Drug: KD019 (tesevatinib)	Kadmon, a Sanofi Company	NULL	Completed	18 Years	62 Years	All	74	Phase 1/Phase 2	United States

First Previous1Next Last